Welcome to our dedicated page for Xtant Medical SEC filings (Ticker: XTNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Xtant Medical Holdings, Inc. (XTNT) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures, including current reports, proxy statements, and financial updates filed with the U.S. Securities and Exchange Commission. Xtant is a global medical technology company focused on orthobiologics for chronic and surgical wound care and sports medicine markets, as well as spinal implant systems for spinal and other orthopedic conditions, and its filings offer detailed insight into how this business is governed and financed.
Among the key documents available are Form 8-K current reports, where Xtant discloses material events. For example, an 8-K dated December 3, 2025 describes the completion of the sale of certain Coflex and CoFix spinal implant assets and all shares of Paradigm Spine GmbH, its international hardware business, to Companion Spine entities, along with related use of proceeds and pro forma financial information. Other 8-Ks report quarterly financial results, the use of non-GAAP adjusted EBITDA, changes to the Board of Directors, the establishment of the annual meeting date, and risk factor updates linked to strategic transactions.
Investors can also review definitive proxy statements on Schedule 14A, such as the document filed on September 15, 2025. That proxy statement outlines the agenda for the annual meeting of stockholders, including director elections, ratification of the independent registered public accounting firm, an amendment to the 2023 Equity Incentive Plan, and advisory votes on executive compensation and its frequency. It also describes corporate governance guidelines, board structure, director and executive compensation, and ownership information.
Through Stock Titan, these XTNT filings are updated as they appear on EDGAR and are accompanied by AI-powered summaries designed to explain the main points in accessible language. Users can quickly see what each filing covers—such as divestiture terms, debt prepayments, equity plan changes, or non-GAAP metric definitions—without reading every page in full.
For those tracking financial performance and capital structure, the filings include condensed consolidated balance sheets, income statement data, and discussions of liquidity, debt arrangements, and credit facility consents. Governance-focused readers can examine voting results from the annual meeting, details of equity incentive plan amendments, and disclosures about significant shareholders and board composition.
By using this XTNT filings page, investors, analysts, and researchers can navigate Xtant Medical’s regulatory history, understand the implications of its asset sales and biologics-focused strategy, and interpret recurring topics such as non-GAAP adjusted EBITDA and risk factors, with AI tools helping to highlight the most important elements in each submission.
Xtant Medical Holdings, Inc. director equity grant reported
A director of Xtant Medical Holdings, Inc. (XTNT) reported receiving 553,797 shares of common stock on November 15, 2025 through a deferred stock unit (DSU) award under the company’s Amended and Restated 2023 Equity Incentive Plan. The DSUs will vest on November 15, 2026, provided the director remains on the board through that date, and each DSU represents a contingent right to receive one share of common stock, with settlement deferred to a later date under the award terms.
Following this award, the director beneficially owns 7,515,570 shares on a direct basis, which includes 1,520,215 shares issuable upon settlement of DSUs that are subject to continued service-based vesting conditions.
Xtant Medical Holdings (XTNT) reported an insider equity grant to a director dated November 15, 2025. The director received 158,228 deferred stock units (DSUs) of common stock at a stated price of $0 under the company’s Amended and Restated 2023 Equity Incentive Plan. Following this grant, the director beneficially owned 517,619 shares directly, including 465,570 shares issuable upon settlement of DSUs, and 1,015,272 shares indirectly through The Platinum Legacy Trust. The new DSU award will vest on November 15, 2026 if the director remains on the board, with settlement of the underlying shares deferred under the DSU award agreement.
Xtant Medical Holdings, Inc. reported that one of its directors received a new equity award in the form of deferred stock units. On November 15, 2025, the director was granted 158,228 deferred stock units (DSUs) of common stock at a price of $0 under the company’s Amended and Restated 2023 Equity Incentive Plan. These DSUs will vest on November 15, 2026, as long as the individual continues to serve as a director through that date. Each DSU represents the right to receive one share of common stock, with actual share delivery deferred to a later date under the award agreement.
Xtant Medical Holdings, Inc. (XTNT) reported that one of its directors received a new equity award in the form of deferred stock units. On November 15, 2025, the director was granted 158,228 deferred stock units (DSUs) of common stock at a reported price of $0 per share. These DSUs will vest on November 15, 2026, provided the individual remains a director through that date. After vesting, the underlying shares will be settled at a later time according to the DSU award agreement. Following this grant, the director beneficially owns 158,228 shares in the form of DSUs under Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan.
Xtant Medical Holdings, Inc. (XTNT) reported that one of its directors received a grant of 158,228 deferred stock units (DSUs) of common stock on November 15, 2025. The DSUs were granted at a price of $0 under the company’s Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, provided the director continues to serve on the board through that date. Each DSU represents the right to receive one share of common stock, with settlement of the vested shares deferred to a later date in line with the DSU award agreement. Following this grant, the reporting person beneficially owns 158,228 shares in the form of DSUs under the plan.
Xtant Medical Holdings, Inc. reported new equity awards for its President and CEO and director on a Form 4. On 11/15/2025, the executive acquired 394,937 shares of common stock at $0, bringing total beneficial ownership to 2,575,274 shares, held directly. These shares are linked to a deferred stock unit award that vests in installments: 98,734 shares on each of November 15, 2026, 2027, and 2028, and 98,735 shares on November 5, 2029, subject to continued employment.
The filing also reports a grant of 789,874 performance stock units (PSUs), representing the maximum of 200% of a 394,937-share target. Each PSU can convert into one share of common stock, vesting in one-third increments based on stock price performance over a three-year period and additional service-based conditions. The executive’s holdings include 1,213,677 shares issuable upon vesting and settlement of restricted stock units and deferred stock units under the company’s 2023 equity incentive plan.
Xtant Medical Holdings (XTNT) reported new equity awards to its Chief Operating Officer on a Form 4. On 11/15/2025, the officer acquired 292,253 shares of common stock at a price of $0 through a deferred stock unit (DSU) award, bringing total beneficial ownership of common stock to 670,866 shares held directly. The DSU grant will vest in four installments: 73,063 shares on each of November 15, 2026, November 15, 2027, and November 15, 2028, and 73,064 shares on November 5, 2029, subject to continued employment, with settlement of shares deferred under the award terms.
The filing also reports a grant of 584,506 performance stock units (PSUs) at a price of $0, which represent a contingent right to receive an equal number of common shares. These PSUs can vest in one-third increments based on stock price performance goals over a three-year period and additional service-based conditions, with 584,506 derivative securities beneficially owned following the grant. The footnotes note that existing holdings include shares issuable under prior RSU and DSU awards from the company’s equity incentive plans.
Xtant Medical Holdings reported an equity award to its CFO and Assistant Secretary. On 11/15/2025, the executive received 263,291 deferred stock units (DSUs) at a price of $0, increasing his beneficial ownership of common stock to 851,465 shares held directly.
The DSUs vest in installments of 65,822 shares on each of November 15, 2026, November 15, 2027, and November 15, 2028, and 65,825 shares on November 5, 2029, subject to continued employment, with settlement deferred under the award terms. The filing also reports 526,582 performance stock units (PSUs), representing 200% of a 263,291-share target, which can convert into common stock based on stock price performance over a three-year period and additional service-based vesting conditions.
Xtant Medical Holdings (XTNT) furnished an update on its business by announcing financial results for the three and nine months ended September 30, 2025. The results are provided in a press release attached as Exhibit 99.1 and are furnished, not filed, under the Exchange Act.
The company highlighted its use of non‑GAAP adjusted EBITDA, defined as net income (loss) from operations before depreciation and amortization, interest, and taxes, further adjusted for separation‑related expenses, non‑cash compensation, divestiture/acquisition‑related expenses, acquisition‑related fair value adjustments, and unrealized foreign currency translation gains or losses.
Xtant notes that adjustments include expenses tied to its pending divestiture of non‑core Coflex/CoFix assets and its international hardware business. A reconciliation to GAAP metrics appears in the press release.
Xtant Medical Holdings (XTNT) reported a profitable Q3 2025. Total revenue was $33.3 million, up from $27.9 million a year ago, driven by $27.8 million of product sales and $5.5 million of license revenue. Gross margin improved to 66.1% from 58.4%, and net income reached $1.3 million versus a $5.0 million loss last year.
For the nine months, revenue rose to $101.6 million from $85.8 million and net income was $4.9 million compared with a $13.3 million loss. Cash and cash equivalents were $10.4 million as of September 30, 2025, with $11.3 million drawn on the line of credit and $17.4 million of long‑term debt. Share count was 140,004,240 as of November 7, 2025.
The company received $7.5 million in non‑refundable deposits tied to the pending sale of Coflex/CoFix assets and its international hardware business and prepaid a portion of its term loan under MidCap consents. U.S. sales accounted for about 91% of revenue; bill‑and‑hold contributed $0.6 million in the quarter.